Skip to main content

Advertisement

SpringerLink
Log in

Aspirin and acetaminophen: Should they be available over the counter?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Traditional nonsteroidal anti-inflammatory drugs block cyclooxygenase (COX). They are the most widely used drugs for pain relief. They are indispensable for their effects but are condemned for their adverse drug reactions. Two COX inhibitors, acetaminophen and aspirin, are the most widely used over-the-counter drugs. They have low (but useful) therapeutic activity, but they are endowed with specific risks that are not seen with most other COX inhibitors. Both are lethal if taken in overdose. Each is stigmatized by severe adverse effects. Aspirin results in prolonged inhibition of blood coagulation, and acetaminophen can result in liver toxicity at normal dose and liver failure at higher dose. Both drugs cause many deaths every year. We recommend that the status of both drugs be changed to prescription only. Their continued availability over the counter poses an unacceptable risk to the general population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lipsky PE, Abramson SB, Breedveld FC, et al.: Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 2000, 27:1338–1340.

    PubMed  CAS  Google Scholar 

  2. Strand V: Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007, 370:2138–2151.

    Article  PubMed  CAS  Google Scholar 

  3. Hinz B, Brune K: Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci 2008, 29:391–397.

    Article  PubMed  CAS  Google Scholar 

  4. Kearney PM, Baigent C, Godwin J, et al.: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302–1308.

    Article  PubMed  CAS  Google Scholar 

  5. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102.

    Article  PubMed  CAS  Google Scholar 

  6. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080.

    Article  PubMed  CAS  Google Scholar 

  7. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330:1366.

    Article  PubMed  CAS  Google Scholar 

  8. Farooq M, Haq I, Qureshi AS: Cardiovascular risks of COX inhibition: current perspectives. Expert Opin Pharmacother 2008, 9:1311–1319.

    Article  PubMed  CAS  Google Scholar 

  9. Warner TD, Mitchell JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004, 18:790–804.

    Article  PubMed  CAS  Google Scholar 

  10. Jenkins C, Costello J, Hodge L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004, 328:434.

    Article  PubMed  CAS  Google Scholar 

  11. Rubenstein JH, Laine L: Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004, 20:373–380.

    Article  PubMed  CAS  Google Scholar 

  12. Patrono C, García Rodríguez LA, Landolfi R, Baigent C: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373–2383.

    Article  PubMed  CAS  Google Scholar 

  13. Brodie BB, Axelrod J: The fate of acetophenetidin in man and methods for the estimation of acetophenetidin and its metabolites in biological material. J Pharmacol Exp Ther 1949, 97:58–67.

    PubMed  CAS  Google Scholar 

  14. Hinz B, Cheremina O, Brune K: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008, 22:383–390.

    Article  PubMed  CAS  Google Scholar 

  15. Scanzello CR, Moskowitz NK, Gibofsky A: The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep 2008, 10:49–56.

    Article  PubMed  Google Scholar 

  16. Botting RM: Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 2000, 31(Suppl 5):S202–S210.

    Article  PubMed  CAS  Google Scholar 

  17. Kis B, Snipes JA, Busija DW: Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005, 315:1–7.

    Article  PubMed  CAS  Google Scholar 

  18. Rahme E, Barkun A, Nedjar H, et al.: Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008, 103:872–882.

    Article  PubMed  CAS  Google Scholar 

  19. Niemi TT, Backman JT, Syrjälä MT, et al.: Platelet dysfunction after intravenous ketorolac or propacetamol. Acta Anaesthesiol Scand 2000, 44:69–74.

    Article  PubMed  CAS  Google Scholar 

  20. Mour G, Feinfeld DA, Caraccio T, McGuigan M: Acute renal dysfunction in acetaminophen poisoning. Ren Fail 2005, 27:381–383.

    PubMed  CAS  Google Scholar 

  21. Chan AT, Manson JE, Albert CM, et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578–1587.

    Article  PubMed  CAS  Google Scholar 

  22. Forman JP, Stampfer MJ, Curhan GC: Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005, 46:500–507.

    Article  PubMed  CAS  Google Scholar 

  23. Watkins PB, Kaplowitz N, Slattery JT, et al.: Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006, 296:87–93.

    Article  PubMed  CAS  Google Scholar 

  24. Björnsson E, Jerlstad P, Bergqvist A, Olsson R: Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005, 40:1095–1101.

    Article  PubMed  Google Scholar 

  25. Krähenbuhl S, Brauchli Y, Kummer O, et al.: Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage. Digestion 2007, 75:232–237.

    Article  PubMed  Google Scholar 

  26. Mahadevan SB, McKiernan PJ, Davies P, Kelly DA: Paracetamol induced hepatotoxicity. Arch Dis Child 2006, 91:598–603.

    Article  PubMed  CAS  Google Scholar 

  27. Squires RH Jr, Shneider BL, Bucuvalas J, et al.: Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006, 148:652–658.

    Article  PubMed  Google Scholar 

  28. Lee WM: Acetaminophen toxicity: changing perceptions on a social/medical issue. Hepatology 2007, 46:966–970.

    Article  PubMed  Google Scholar 

  29. Bradley JD, Brandt KD, Katz BP, et al.: Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87–91.

    PubMed  CAS  Google Scholar 

  30. Pincus T, Koch GG, Sokka T, et al.: A randomized, doubleblind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587–1598.

    Article  PubMed  CAS  Google Scholar 

  31. Case JP, Baliunas AJ, Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003, 163:169–178.

    Article  PubMed  CAS  Google Scholar 

  32. Pincus T, Koch G, Lei H, et al.: Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931–939.

    Article  PubMed  CAS  Google Scholar 

  33. Towheed TE, Maxwell L, Judd MG, et al.: Acetaminophen for osteoarthritis. Cochrane Database System Rev 2006, 1:CD004257.

    Google Scholar 

  34. Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006, 116:4–15.

    Article  PubMed  CAS  Google Scholar 

  35. Lanas A, Scheiman J: Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007, 23:163–173.

    Article  PubMed  CAS  Google Scholar 

  36. Kaufman DW, Kelly JP, Sheehan JE, et al.: Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993, 53:485–494.

    PubMed  CAS  Google Scholar 

  37. Fosbøl E, Gislason G, Jacobsen S, et al.: Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2008 (in press).

Download references

Author information

Authors and Affiliations

  1. Department of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nuremberg, Fahrstrasse 17, 91054, Erlangen, Germany

    Kay Brune

Authors
  1. Kay Brune
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Burkhard Hinz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivan Otterness
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kay Brune.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brune, K., Hinz, B. & Otterness, I. Aspirin and acetaminophen: Should they be available over the counter?. Curr Rheumatol Rep 11, 36–40 (2009). https://doi.org/10.1007/s11926-009-0006-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0006-4

Keywords

Search

Navigation